Want to see AU:RAC full AI Analyst Report?
RAC Stock Chart & Stats
AU$2.70
-AU$0.03(-2.27%)
At close: 4:00 PM EST
AU$2.70
-AU$0.03(-2.27%)
Day’s Range― - ―
52-Week RangeAU$1.13 - AU$4.90
Previous CloseN/A
Volume68.10K
Average Volume (3M)373.28K
Market Cap
AU$447.04M
Enterprise ValueAU$450.36M
Total Cash (Recent Filing)AU$20.94M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta0.41
Next Earnings
Sep 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.05
Shares Outstanding196,068,940
10 Day Avg. Volume310,625
30 Day Avg. Volume373,283
Financial Highlights & Ratios
PEG Ratio0.63
Price to Book (P/B)12.69
Price to Sales (P/S)33.63
P/FCF Ratio-44.42
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.1
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetZero debt materially lowers financing and refinancing risk and preserves flexibility for a clinical-stage biotech. A debt-free structure reduces interest burden and supports strategic options like partnering, licensing or equity raises without immediate solvency pressure.
Improving Gross Margin And Cost Performance (FY2025)A meaningful gross margin improvement and lower operating costs in FY2025 indicate better revenue quality and tighter cost discipline. If sustained, margin expansion provides a clearer path to positive operating leverage as revenues scale or as clinical milestones enable higher-value commercialization.
Focused Clinical-stage Oncology Pipeline (bisantrene/RC220)A concentrated pipeline around a single, repurposed oncology asset gives strategic clarity and specialized expertise. This focus can accelerate trial design, regulatory strategy, and partner interest, increasing odds of value-creating collaborations or licensing if clinical data validate efficacy.
Bears Say
Persistent Negative Operating And Free Cash FlowConsistent negative operating and free cash flow forces reliance on external funding, increasing dilution or need for partnerships. Even with improvement, ongoing cash burn erodes runway and constrains sustained R&D or commercialization spending without new capital or material non-dilutive funding.
Ongoing Net Losses And Negative ProfitabilityChronic operating losses reduce equity and limit reinvestment capacity, lengthening the path to self-sustaining operations. For a clinical-stage biotech, repeated losses increase dependence on milestone events or financing and magnify downside if clinical outcomes delay or fail to meet expectations.
Revenue Volatility And Sharp FY2025 DeclineSignificant revenue swings complicate forecasting and operational planning, undermining predictable scaling. A sharp revenue drop signals uneven commercialization or milestone timing, making it harder to sustain hiring, trials and fixed costs without intermittent capital infusions or firm partnership commitments.
Race Oncology Ltd. News
RAC FAQ
What was Race Oncology Ltd.’s price range in the past 12 months?
Race Oncology Ltd. lowest share price was AU$1.13 and its highest was AU$4.90 in the past 12 months.
What is Race Oncology Ltd.’s market cap?
Race Oncology Ltd.’s market cap is AU$447.04M.
When is Race Oncology Ltd.’s upcoming earnings report date?
Race Oncology Ltd.’s upcoming earnings report date is Sep 01, 2026 which is in 59 days.
How were Race Oncology Ltd.’s earnings last quarter?
Race Oncology Ltd. released its earnings results on Feb 27, 2026. The company reported -AU$0.023 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.023.
Is Race Oncology Ltd. overvalued?
According to Wall Street analysts Race Oncology Ltd.’s price is currently Overvalued.
Does Race Oncology Ltd. pay dividends?
Race Oncology Ltd. does not currently pay dividends.
What is Race Oncology Ltd.’s EPS estimate?
Race Oncology Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Race Oncology Ltd. have?
Race Oncology Ltd. has 196,068,940 shares outstanding.
What happened to Race Oncology Ltd.’s price movement after its last earnings report?
Race Oncology Ltd. reported an EPS of -AU$0.023 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.646%.
Which hedge fund is a major shareholder of Race Oncology Ltd.?
Currently, no hedge funds are holding shares in AU:RAC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Race Oncology Ltd. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:RAC Sentiment 98%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth AU$30.4K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
110.34%
12-Months-Change
Fundamentals
Return on Equity
-47.44%
Trailing 12-Months
Asset Growth
14.28%
Trailing 12-Months
Company Description
Race Oncology Ltd.
Headquartered in Sydney, Australia, Race Oncology Limited is a precision oncology company focused on advancing its lead therapeutic, Zantrene. This potent small molecule compound acts as an inhibitor of the fatso/fat mass and obesity associated protein (FTO) and is currently undergoing Phase II/III clinical trials. Zantrene is being investigated for its potential to treat a range of cancers, including melanoma, clear cell renal cell carcinoma, acute myeloid leukaemia, breast cancer, and ovarian cancer. The company maintains an active preclinical research program with the University of Newcastle, focusing on Zantrene, and has also forged a strategic alliance with the University of Wollongong to assess various formulations of the drug. Established in 2011, Race Oncology Limited adopted its current name in July 2016, having previously operated as Coronado Resources Limited.
Technical Analysis
Imugene
―
Immutep Ltd
―
Telix Pharmaceuticals
―
Clarity Pharmaceuticals Ltd.
―
Radiopharm Theranostics Limited
―
Options Prices
Currently, No data available
---